Heart failure & cardiomyopathiesRandomised controlled trial
Finerenone in Heart Failure with Mildly Reduced or Preserved Ejection Fraction
- Randomised controlled trial
- international
- double-blind
- placebo-controlled
Authors' conclusion
In patients with heart failure and mildly reduced or preserved ejection fraction, finerenone resulted in a significantly lower rate of a composite of total worsening heart failure events and death from cardiovascular causes than placebo.
Study context
- Population
- Patients with HF and LVEF of 40% or greater (mildly reduced or preserved EF)
- Participants
- 3,003 vs 2,998
- Comparison
- Finerenone vs placebo, in addition to usual therapy
- Finerenonen = 3,003
- Placebon = 2,998reference
- Primary endpoint
- Composite of:
- Total worsening HF events (first or recurrent unplanned hospitalization or urgent visit for HF)
- CV death
- Follow-up
- Median 32 months
Primary result
As reported in the abstract
Rate ratio
0.84
95% CI 0.74–0.95
P = 0.007
Events by treatment group
Finerenone
1083
events
Placebo
1283
events
Finerenone vs Placebo
rate ratio 0.84 (95% CI 0.74–0.95); P = 0.007
Further findings
| Outcome | Finerenone | Placebo | Estimate | P value | |
|---|---|---|---|---|---|
| Total worsening HF events | 842 events | 1024 events | rate ratio 0.82 (95% CI 0.71–0.94) | P = 0.006 | |
| CV death | 8.1% | 8.7% | HR 0.93 (95% CI 0.78–1.11) | ||
| 0.512Ratio (log scale) |
Safety
Hyperkalemia and hypokalemia
- Finerenone associated with increased risk of hyperkalemia and reduced risk of hypokalemia
Original publication
Finerenone in Heart Failure with Mildly Reduced or Preserved Ejection Fraction. N Engl J Med. Published 1 September 2024. doi:10.1056/nejmoa2407107
Summarised from the published abstract; every number is checked against it